<caption><image_26>The image is a screenshot of a news report in Korean. It shows a woman in a red dress standing in front of a green background. She is holding a pen in her hand and appears to be speaking. On the left side of the image, there is a table with three columns and three rows. The first column lists the percentage of people who have been diagnosed with cancer, the second column shows the number of patients, and the third column displays the percentage that has been diagnosed. The table also has a legend at the bottom that explains the meaning of each column.</caption><transcript><audio_27> 한 적이 있는데 실제로 지금 지수 대비 아웃퍼폼하고 있고요. 지금은 한번 진입을 해볼 만한 시기이다 이렇게 좀 평가를 해주신 것 같아요. 저희 어떤 종목 공략할지 종목도 바로 공개해 주시죠. 셀티리온입니다. 셀티리온은 사실은</transcript><transcript><audio_28> 실질적인 실적 증가는 내년인데요. 올해는</transcript><transcript><audio_29> 네.</transcript><transcript><audio_30> 보고 있습니다. 하지만 내년에는 일단 실적 성장이 크게 나타날 것으로 보이는데 앞서 말씀드렸던 유플라이마가 내년 7월부터 미국에서 판매가 시작되고요. 여기에 막바지 임상 진행 중인 복제약들도 출시 예정으로 보이는데 건선치료에</transcript> I once said that it could be done, but in fact, it is currently outperforming the index. It is an example of a way to enter right now. I think you have given such a good evaluation. My overall goal of targeting which stocks we will target is Tyrion, who will immediately use public support. In fact, Celltrion's actual stock price increase of 0 0 may still be insufficient, but the current stock price has broken through the bottom and seems to be on the verge of turning a corner, so I see it as a stock that needs attention. In reality, first of all, next year is when actual performance will increase. In the case of this year,  The increase in last year's outing means that going out with a certain L's height, the body does not have any significant efficacy, so sales are almost certain to be excluded, and sales of some related diagnostic kits due to the coronavirus are also certain to decrease, so this year's performance growth will be somewhat limited.  I'm looking at it, but next year, it looks like it will actually appear very big. As I mentioned earlier, LimeA, the leaf of which I mentioned earlier, will start selling in the U.S. in July of next year. Generic drugs are also in the final stages of clinical trials, and it looks like they are scheduled to be released as well.
{"source": "grass-yt-cc-by.1BgTv5KqG6Y|shard_10011_17|create_multimodal_data.extract_yt_and_generate_transcripts.26|shard_10011|create_multimodal_data.generate_captions.44|shard_10011|create_multimodal_data.generate_captions.44", "params": {"id": "1BgTv5KqG6Y", "channel_id": "UC8Sv6O3Ux8ePVqorx8aOBMg", "duration": 461, "view_count": 1202, "age_limit": 0, "like_count": 25, "channel_follower_count": 277000, "license": "Creative Commons Attribution license (reuse allowed)", "channel_is_verified": true, "uploader_id": "@Edaily_TV", "yt_tar_file": "/leonardo_work/EUHPC_E03_068/audio/fixed_download/grass-yt-cc-by//shard_10011/1BgTv5KqG6Y.tar.gz"}}